This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Justin Llewellyn-Jones has been appointed chief operating officer (COO), joining from Broadridge where he most recently served as chief product officer and head of capitalmarkets, North America (equities, FX and derivatives). Heffernan will join from Flow Traders, where he has been head of fixed income sales since 2019.
2019 was a banner year for billion-dollar life sciences M&A transactions. A wave of big-ticket transactions by global pharmaceutical companies drove life sciences M&A activity to its fourth-largest year on record in 2019, with aggregate deal value in the pharmaceutical, medical and biotech industry reaching $234.2
He re-joined the agency only broker-dealer after also previously serving as a director for almost three years from 2019 to 2022. Sparacino has an extensive career in options trading after also previously in senior sales and options roles for four years at Dash Financial Technologies and six and a half years at ConvergEx Group.
Redburn Atlantic has expanded its UK and European execution business with two new heads of sales trading. Tony Atkins was appointed UK head of sales trading. Atkins joined Redburn Atlantic in 2004 as a sales trader having previously served for eight years at Morgan Grenfell and two years at Marathon Asset Management.
Kepler Cheuvreux’s execution sales specialist Cherry Albon is set to join Berenberg next year, according to multiple sources familiar with the matter. Albon has been appointed associate director, senior sales for EMEA electronic trading and program trading, set to join the firm in February next year.
Previously in his career, Paparella ran the institutional structured products Latin America desk for RBC CapitalMarkets. Wiedmann brings more than 18 years of experience in asset management and sales in the German-speaking markets. He succeeds Robert Begbie, chief executive, commercial and institutional.
Periculum began formally working with Mi-Tech in December 2019 to find a buyer that could strengthen the Company’s global supply chain, realize significant strategic synergies and qualify to own Mi-Tech ’s portfolio of customer relationships that included controlled and classified federal government programs.
The newly merged transatlantic broker, Redburn Atlantic, will be headquartered in London, offering clients broader research coverage, corporate access and research sales alongside agency execution capabilities. Rothschild & Co first took a minority investment in Redburn in 2019 to capitalise on the investment research fallout of Mifid II.
In the public markets, the use of public auctions for business sales is commonplace. We saw how in 2019, Les Schwab Tire Centers publicly announced that they hired Goldman Sachs to sell the company. Now, in the private capitalmarkets, sellers are more concerned with confidentiality, so no one finds out a business is for sale.
For example, such an offer may entice certain shareholders because it avoids the brokerage commissions that are associated with a typical sale. Catalyst Capital Group Inc. On August 2, 2019, Mach Acquisition Inc. (“ Mach” ) offered to purchase 19.5% Intervention of Regulators. and Hudson’s Bay Co. Group Mach Acquisition Inc.
“If I look at who the biggest players in the European markets were 10 years ago it’s very different to who they are today,” says Bobby Molavi, head of EMEA execution services and European primary distribution for equity capitalmarkets at Goldman Sachs.
Dominic Rieb-Smith, managing director, international head, prime services sales, JP Morgan, refers to the past year as “a standout”. Over the past year, each of the top 25 primes have increased their market share – according to Convergence – with 16 of those experiencing double-digit percentage growth.
Outsourced trading, though undoubtedly a contentious topic, is something that has been around in capitalmarkets for decades in some form or another. However, an undeniable surge has occurred across the trading sphere over the last few years, with decidedly mixed results.
The pandemic marked a seminal moment across the capitalmarkets, effectively drawing a line between the old world and the new. Those investments bolster their technology, scale and the level of talent and experience on their desks, to the point where the sales pitch becomes unavoidable for some.
As a result, the combined company following a de-SPAC transaction may consider filing a resale Form S-1 registration statement that allows for greater flexibility of sales of the combined company’s shares in the market. Another common feature of SPACs and IPOs is the lock-up. Larger PIPEs.
John Extract F ollowing the allegations made public by Viceroy Research LLC, Wilmington, Delaware, USA, in the role of a short seller in September 2020, GRENKE AG’s financial reporting as at the immediately subsequent reporting date has a particularly indicative effect from the perspective of the capitalmarket and other key stakeholders.
19 treatments from Pfizer, Merck and potentially others hitting the market soon , we expect Big Pharma to continue to parlay this cash flow into growth in other areas of strategic focus. on transactions over 2019’s mega?mergers. These players have looked further afield to add new capabilities and pipeline assets. closing friction.
Francesca joins us having spent five years at Capital Group and, in addition to trading equities, will help us enhance our position across the capitalmarkets structure. She has also worked extensively across the firm, starting out as an investment control associate in March 2019 before moving on to an analyst role.
We organize all of the trending information in your field so you don't have to. Join 38,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content